

Mark R Trusheim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5419821/publications.pdf>

Version: 2024-02-01

25
papers

971
citations

687363

13
h-index

610901

24
g-index

28
all docs

28
docs citations

28
times ranked

1485
citing authors

#	ARTICLE	IF	CITATIONS
1	Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 287-293.	46.4	438
2	Quantifying factors for the success of stratified medicine. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 817-833.	46.4	90
3	Alternative State-Level Financing for Hepatitis C Treatmentâ€”The â€œNetflix Modelâ€• <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1977.	7.4	58
4	Translational Medicine Guide transforms drug development processes: the recent Merck experience. <i>Drug Discovery Today</i> , 2016, 21, 517-526.	6.4	50
5	Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System. <i>Value in Health</i> , 2019, 22, 621-626.	0.3	48
6	Surface-modified photochemistry. Preparation of silica-supported triiron dodecacarbonyl via irradiation of absorbed iron pentacarbonyl. <i>Journal of the American Chemical Society</i> , 1982, 104, 6590-6596.	13.7	38
7	A Useful and Sustainable Role for Nâ€¢ofâ€¢1 Trials in the Healthcare Ecosystem. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 224-232.	4.7	25
8	Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues. <i>Drug Discovery Today</i> , 2022, 27, 17-30.	6.4	22
9	Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. <i>Drug Discovery Today</i> , 2021, 26, 399-415.	6.4	20
10	Economic challenges and possible policy actions to advance stratified medicine. <i>Personalized Medicine</i> , 2012, 9, 413-427.	1.5	19
11	Comparison of Stakeholder Metrics for Traditional and Adaptive Development and Licensing Approaches to Drug Development. <i>Therapeutic Innovation and Regulatory Science</i> , 2013, 47, 474-483.	1.6	19
12	Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?. <i>Forum for Health Economics and Policy</i> , 2010, 13, .	0.8	18
13	Investigating investment in biopharmaceutical R&D. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 673-674.	46.4	16
14	Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation. <i>Therapeutic Innovation and Regulatory Science</i> , 2016, 50, 347-354.	1.6	15
15	The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics. <i>Drug Discovery Today</i> , 2015, 20, 1439-1450.	6.4	13
16	Biosimilars And Follow-On Products In The United States: Adoption, Prices, And Users. <i>Health Affairs</i> , 2021, 40, 989-999.	5.2	13
17	Understanding the Rewards of Successful Drug Development â€” Thinking Inside the Box. <i>New England Journal of Medicine</i> , 2020, 382, 473-480.	27.0	12
18	Uncertain prognosis for high-quality diagnostics: clinical challenges, economic barriers and needed reforms. <i>Pharmacogenomics</i> , 2013, 14, 325-334.	1.3	11

#	ARTICLE	IF	CITATIONS
19	Characterization of annual disease progression of multiple sclerosis patients: A population-based study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 786-794.	3.0	10
20	Defining and quantifying the use of personalized medicines. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 896-897.	46.4	8
21	The Janus initiative: A multi-stakeholder process and tool set for facilitating and quantifying Adaptive Licensing discussions. <i>Health Policy and Technology</i> , 2014, 3, 241-247.	2.5	8
22	Precision reimbursement for precision medicine: using real world evidence to evolve from trialâ€”project to trackâ€”pay to learnâ€”predict.. <i>Clinical Pharmacology and Therapeutics</i> , 2021, , .	4.7	5
23	Personalized medicine and health economics: is small the new big? A white paper. <i>Israel Medical Association Journal</i> , 2013, 15, 602-7.	0.1	2
24	Data for modelling US projections of product approvals, patients treated, and product revenues for durable cell and gene therapies. <i>Data in Brief</i> , 2022, 41, 107891.	1.0	1
25	Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?. <i>SSRN Electronic Journal</i> , 2010, , .	0.4	0